Demand for ‘Hollywood’ weight loss drugs Ozempic and Wegovy, has turned a once-niche Danish pharmaceutical firm into Europe’s most valuable company. As Novo Nordisk’s stock price skyrockets, it’s outsizing Denmark’s economy, and its growth has been credited with single-handedly staving off a national recession. James Reynolds examines how Novo is viewed by Danes, and what it’s doing to stay ahead of international competitors, with BBC reporter in Copenhagen, Adrienne Murray.

The Global Story brings you trusted insights from BBC journalists worldwide. We’re keen to hear from you, wherever you are in the world. We want your ideas, stories and experiences to help us understand and tell The Global Story. Email us at theglobalstory@bbc.com You can also message us or leave a voice note via WhatsApp on +44 330 123 9480. #TheGlobalStory

This episode was made by Laurie Kalus and Neal Razzell. The technical producers were Dafydd Evans and Mike Regaard. The assistant editor is Sergi Forcada Freixas and the senior news editor is Jonathan Aspinwall.

How Denmark became a super producer of viral 'skinny jabs' 22:43 Share

The Global Story

Shownotes Transcript

How Denmark became a super producer of viral 'skinny jabs'